2 Biotech Stocks With Major Potential Catalysts in 2021

Biotech companies have lots of industry-specific risks to navigate. These include potential regulatory roadblocks and negative results from clinical trials. No company wants to discontinue the development of a drug after having spent millions of dollars on the project. But where there is risk, there is potential reward: Shares of a biotech stock can skyrocket on positive regulatory or trial news. 

That's why it may be worth it for investors to keep an eye on drugmakers that are awaiting decisions from the U.S. Food and Drug Administration (FDA), particularly if the drug being reviewed for approval would be a game-changer. With that in mind, let's look at two companies that find themselves in this exact situation: Provention Bio (NASDAQ: PRVB) and Biogen (NASDAQ: BIIB).

Continue reading

Source Fool.com